Heska Corporation

Catherine A McCall

Eric R Weber

Shirley Wu Hunter

Shumin Yang

Liang Tang

The present invention relates to high molecular weightproteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.

Dermatophagoides nucleic acid molecules

The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).

Feline immunoglobulin E molecules and related methods

The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.

Canine IL-5 proteins and fragments thereof

The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R&#x3b1;) proteins, particularly canine interleuken receptor alpha 1 (IL-13R&#x3b1;1) and canine interleuken receptor alpha 2 (IL-13R&#x3b1;2) proteins. Also included are canine IgG and IL-13R&#x3b1; proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors. Also included are kits containing said molecules or chimera thereof, including their use to evaluate and regulate an immune response in an animal.

Canine IL-13 receptor alpha-1 subunit nucleic acid molecules

Dermatophagoides proteins and uses thereof

The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.

Equine Fc epsilon receptor alpha protein

Cannie IL-5 nucleic acid molecules

Feline immunoglobulin E proteins and compositions thereof

Dermatophagoides proteins and fragments thereof

Anti-equine Fc epsilon receptor alpha chain antibodies and methods to detect IgE

The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R&agr;) proteins, particularly canine interleuken receptor alpha 1 (IL-13R&agr;1) and canine interleuken receptor alpha 2 (IL-13R&agr;2) proteins. Also included are canine IgG and IL-13R&agr; proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors. Also included are kits containing said molecules or chimera thereof, including their use to evaluate and regulate an immune response in an animal.

Compositions and methods related to canine IgG and canine IL-13 receptors

Equine Fc epsilon receptor alpha chain proteins and uses thereof

Feline immunoglobulin E molecules and compositions there of

The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.

Dermatophagoides nucleic acid molecules, proteins and uses thereof

The present invention relates to canine low affinity IgE receptor (CD23) nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, compounds capable of regulating, e.g., inhibiting or activating, the function of such proteins, and methods to identify such regulatory compounds. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies, or regulatory compounds, methods to use such therapeutic compositions, and methods and kits to detect CD23 proteins.

Growing community of inventors

Boulder, CO, United States of America

Catherine A McCall